Yanomet-AM 50/5 Tablet PR is a combination antihypertensive medication containing Amlodipine 5 mg and Metoprolol Succinate 50 mg. Amlodipine, a dihydropyridine calcium channel blocker, acts by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing myocardial oxygen demand. This fixed-dose combination is indicated for the management of essential hypertension and angina pectoris, particularly in patients requiring dual therapy for optimal blood pressure control or symptom relief. The prolonged-release formulation of Metoprolol ensures stable plasma concentrations, enhancing therapeutic efficacy and patient compliance. Yanomet-AM 50/5 Tablet PR should be administered once daily, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects may include dizziness, fatigue, hypotension, and peripheral edema. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy. This combination offers a synergistic approach to cardiovascular risk reduction by targeting multiple pathophysiological mechanisms.